In most countries, prostate cancer incidence and mortality rates decreased or were stable in the most recent five-y ...

Published in Nature Communications, a new study led by the University of Minnesota Medical School and Duke University found ...

Candel Therapeutics, Inc. (NASDAQ:CADL) announced results from a phase 3 trial of CAN-2409 viral immunotherapy in ...

By Karen Roman Candel Therapeutics, Inc. (Nasdaq: CADL) said Phase 3 of its prostate cancer candidate CAN-2409 showed an upgrade in disease-free survival in intermediate-to-high-risk patients. “We ...

Candel Therapeutics' CAN-2409 shows a 14.5% improvement in prostate cancer survival. Discover why CADL stock stays a "Buy" ...

The latest international Kamal Choudhury news and views from Reuters - one of the world's largest news agencies ...

The company’s stock price soared after its prostate cancer drug CAN-2409, met the primary endpoint in a Phase III study.

Candel Therapeutics is a clinical-stage biopharmaceutical company that specializes in developing biological immunotherapies aimed at helping patients fight cancer. The company’s leading product, ...

Prostate cancer vaccines, including dendritic and peptide types, offer hope for improved treatments, but face hurdles in ...

A phase 3 prostate cancer trial of Candel’s oncolytic virus has met its primary endpoint, sending the stock up more than 200% ...

Ryne Sandberg, the legendary Chicago Cubs second baseman and Baseball Hall of Famer, on Tuesday revealed that his metastatic ...

Shares of Candel Therapeutics took flight in premarket trading Wednesday after the clinical-stage biopharmaceutical company said a late-stage study of its CAN-2409 product candidate met its key goal ...